Kaletra (Lopinavir/Ritonavir)

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Kaletra (Lopinavir/Ritonavir)

The Basics | News | Research

See also: Medication Side Effects | Drug Interactions

Brand Name:	Kaletra
Generic Name:	Lopinavir/Ritonavir, LPV/RTV
Adult Single Dose*:	Two tablets (400 mg/100 mg) twice daily or 4 tablets (800 mg/200 mg) once daily
Food & Liquid Restrictions:	Take with or without food. Side effects may be lessened with food.
Drug Class:	PI
* This recommendation is for patients starting HIV treatment. A different dose is recommended for treatment experienced patients.

The Basics

An Overview of Kaletra (Lopinavir/Ritonavir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Lopinavir + Ritonavir (Kaletra) (June 26, 2008)
To read PDF, click here
From AIDS InfoNet
Kaletra (Lopinavir/Ritonavir, LPV/r) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Patient Frequently Asked Questions (November 2007)
Information about the new Kaletra (lopinavir/ritonavir) tablets.
From Abbott Laboratories
Patient Information About Kaletra (Lopinavir/Ritonavir) Tablets (PDF) (November 2007)
From Abbott Laboratories
Kaletra (Lopinavir/Ritonavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Patient Information About Kaletra (Lopinavir/Ritonavir) Capsules (PDF) (July 2007)
From Abbott Laboratories
Lopinavir (Kaletra) (August 15, 2006)
From AIDS Treatment Data Network
Kaletra (Lopinavir/Ritonavir) (November 2005)
To read PDF, click here
From The Center for AIDS
Drug Interactions: Kaletra (August 2004)
From Project Inform
The Debate Over Kaletra (Lopinavir/Ritonavir) "Monotherapy" (August 2004)
From American Foundation for AIDS Research
What Role, Kaletra? (Spring 2001)
To read PDF, click here
In CRIA Update, from AIDS Community Research Initiative of America
Drug Fact Sheet: Lopinavir/Ritonavir (Kaletra) (December 2000)
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
Kaletra (ABT-378/r) Approved (September 22, 2000)
Details and information sources on Kaletra (lopinavir plus low-dose ritonavir), a newly approved protease inhibitor approved last week.
In AIDS Treatment News, from AIDS Treatment News
FDA Approves Kaletra for HIV Infection (September 15, 2000)
FDA issues accelerated approval for enhanced protease inhibitor.
From U.S. Food and Drug Administration
Lopinavir: The Most Potent Protease Inhibitor (Summer 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation

News

New Pediatric Dosing Information for Kaletra, Patients 14 Days to 6 Months and 12-18 Years of Age and Update Information on Coadministration With Midazolam (PDF) (June 23, 2008)
From U.S. Food and Drug Administration
Newly-Unsealed Documents Shed Light on Abbott Labs' 400% Norvir Price Hike (May 12, 2008)
Union, consumer groups decry Abbott for putting profits before HIV/AIDS patients' needs
In A Closer Walk: A Film by Robert Bilheimer, from Community Catalyst
Abbott Receives FDA Approval for Lower-Dose of Kaletra for Children (November 13, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Kaletra and Accidental Overdose in Children (PDF) (August 16, 2007)
Direct Healthcare Professional communication on Kaletra (lopinavir/ritonavir) solution and accidental overdose in children.
From Abbott Laboratories
Abbott, FDA Warn About Possible Overdose of Antiretroviral Kaletra in Children (August 15, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Student Global AIDS Campaign Responds to Abbott's Decision to Reduce Price of Kaletra in Low and Middle Income Countries (April 10, 2007)
From Student Global AIDS Campaign
The State of Access to Kaletra (April-July 2006)
In GMHC Treatment Issues, from Gay Men's Health Crisis
FDA Approval of New Formulation of Kaletra (October 28, 2005)
From U.S. Food and Drug Administration
Brazil Nears New Deal With Abbott on Price of Kaletra (October 4, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention

Research

Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers. (February 14, 2008)
In Journal of Acquired Immune Deficiency Syndromes
Atazanavir Noninferior to Lopinavir in Treatment-Naive HIV-Infected People (February 6, 2008)
From The Body PRO
Lopinavir/Ritonavir Monotherapy or Plus Zidovudine and Lamivudine in Antiretroviral-Naive HIV-Infected Patients (January 30, 2008)
In AIDS
EACS: Kaletra Monotherapy May Need Excellent Adherence to Work (October 31, 2007)
In aidsmap.com
ATAZIP: Switching Away From Lopinavir/Ritonavir (July 25, 2007)
Switching from lopinavir/ritonavir (Kaletra) to atazanavir (Reyataz)/ritonavir (Norvir) maintains virologic efficacy and leads to sustained improvements in lipid levels. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Darunavir Superior to Lopinavir in 48-Week Study in Treatment-Experienced Patients (July 6, 2007)
From aidsmap.com
Kaletra-Based Regimens May Suppress Viral Load Despite Missed Doses (May 1, 2007)
In Journal of Acquired Immune Deficiency Syndromes
Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Predictors of Virologic Rebound on Lopinavir/Ritonavir Monotherapy (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Resistance Analysis of Lopinavir/Ritonavir Maintenance Therapy Study (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The GEMINI Study: Are Saquinavir + Ritonavir and Lopinavir/Ritonavir Twins? (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
Long-Term Lopinavir/Ritonavir Treatment and CD4+ Cell Responses (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Reducing the Dose of Lopinavir/Ritonavir Is Associated With Low-Level Viremia (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy (August 17, 2006)
In XVI International AIDS Conference
Switching From Lopinavir/Ritonavir to Unboosted Atazanavir May Yield Benefits, but Verdict Remains Uncertain (August 17, 2006)
In XVI International AIDS Conference
Treating Patients With Lopinavir/Ritonavir Alone Still Risky (August 17, 2006)
In XVI International AIDS Conference
Acid-Reducing Agents Reduce Atazanavir Drug Levels but Not Lopinavir/Ritonavir Levels (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
During the Third Trimester of Pregnancy Lopinavir/Ritonavir Dose Should Be Increased, Study Finds (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
Better Adherence With Once-Daily Versus Twice-Daily Lopinavir/Ritonavir: New Tablet Formulation Has Improved GI Tolerability (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Brazil, Abbott Reach Deal to Lower Price on Antiretroviral Drug Kaletra (October 12, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Brazil Again Seeks Negotiations With Abbott to Lower Price on Antiretroviral Drug Kaletra (August 19, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Coming Soon: New Lopinavir/Ritonavir (Kaletra) Formulation Allowing for 2-Tablet, Twice-Daily Dosing (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Full Virologic Suppression Can Be Maintained With Lopinavir/Ritonavir Alone; Single-Agent Therapies Worth Further Investigation (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Once-Daily Lopinavir/Ritonavir Approved for Treatment-Naive Patients (April 29, 2005)
From U.S. Food and Drug Administration
Notice of Important New Drug Interactions With Norvir, Kaletra (March 30, 2005)
New interactions noted with fluticasone (a component of Flonase nasal spray) and trazodone (Desyrel, an antidepressant).
From U.S. Food and Drug Administration
Don't Combine Fosamprenavir and Lopinavir/Ritonavir (February/March 2005)
From The Body PRO
Lopinavir/Ritonavir Monotherapy in Treatment-Naive Patients (January 2005)
Part of HIV JournalView's Top 10 Research Reports of 2004.
From The Body PRO
Kaletra Monotherapy Controversy: amfAR Publishes Overview (October 26, 2004)
In AIDS Treatment News, from AIDS Treatment News
Summary of Kaletra (Lopinavir/Ritonavir) Labeling Revisions (October 22, 2004)
Long-term efficacy and safety results from two phase II trials have now been included.
From U.S. Food and Drug Administration
Drug Development News: Abbott (May/June 2004)
New formulations of lopinavir/ritonavir (Kaletra) and ritonavir are in the works.
In GMHC Treatment Issues, from Gay Men's Health Crisis
First Case of Potential PI Cross-Resistance Reported After Lopinavir Failure (April 29, 2004)
From aidsmap.com
Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network
Lexiva + Kaletra -- Still a Bad Idea (March/April 2004)
A short review of a study presented at CROI 2004.
In Positively Aware, from Test Positive Aware Network
Drug Monitoring, NRTI Activity Help Predict Lopinavir/Ritonavir Response in Experienced Patients (February 11, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Nelfinavir, Lopinavir/Ritonavir Appear Safe for Hepatitis C Patients (February 10, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Boosted Atazanavir Similar to Boosted Lopinavir in Treatment-Experienced Patients (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Once-Daily Lopinavir/Ritonavir as Effective as Twice-Daily, but Greater Side Effects Are Concern (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Unboosted Atazanavir Better on Insulin Sensitivity Compared to Lopinavir/Ritonavir (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
HIV Drug Kaletra Proves Effective in Five-Year Study (September 16, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Kaletra "Monotherapy" Safe and Efficacious for Treatment-Naive Patients (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Treatment Regimens Containing Efavirenz, Nevirapine or Kaletra Are the Most Potent Options for Patients Starting Therapy (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
908 vs. Kaletra: Comparable for Experienced Patients, Not for Naive (July 28, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Kaletra: Could Upping the Dose Overcome Resistance? (July 18, 2003)
A 67 percent increase in the lopinavir/ritonavir dose was found to be far more effective than increasing only the ritonavir.
From aidsmap.com
Research From the 42nd ICAAC: High Lopinavir Levels Predict High Lipids (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Antiretroviral Update: Lopinavir/Ritonavir (Kaletra) (November 2001)
In HEPP News, from Brown Medical School
Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
Efficacy of Lopinavir in Heavily Pretreated Patients (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
A New Side Effect From Kaletra? (May 25, 2001)
From Canadian AIDS Treatment Information Exchange
FDA Issues Pancreatitis Warning for New Drug Lopinavir (March 2001)
In WISE Words, from Project Inform
Head-to-Head Study of Two Protease Inhibitors (March 2001)
To read PDF, click here
In Project Inform Perspective, from Project Inform
Kaletra: Abbott Joins the Bandwagon (Spring 2001)
Recap of Kaletra's Phase III trial results and expanded access program.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Lopinavir (Kaletra) Update: Study M97-765 (September 2000)
In Research Initiative/Treatment Action!, from The Center for AIDS
Lopinavir/Ritonavir (Norvir) Plus Either Efavirenz (Sustiva) or Nevirapine (Viramune) and Two NRTIs (Autumn 2000)
Highlights from the XIII International AIDS Conference.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
New Drugs in Development (Fall 2000)
Lopinavir (Kaletra; ABT-378/r).
In CRIA Update, from AIDS Community Research Initiative of America
Kaletra™ (ABT-378/r) Early Access Program Can Accept More Patients (August 18, 2000)
More patients can now receive this experimental protease inhibitor.
In AIDS Treatment News, from AIDS Treatment News
ABT-378/Ritonavir and Efavirenz for Salvage Therapy in Patients Multiply-Exposed to PIs (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
Kaletra™ (ABT-378/r) Application for Accelerated Approval (June 23, 2000)
Overview of new protease inhibitor moving toward wider use.
In AIDS Treatment News, from AIDS Treatment News
Lopinavir: The Most Potent Protease Inhibitor (Summer 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Expanded Access Program for ABT-378/r Amended (May 2000)
In Positive Living, from AIDS Project Los Angeles
Lopinavir Shows Good Activity (April 2000)
In Project Inform Perspective, from Project Inform
Selected Highlights From the 7th CROI: ABT-378 (Lopinavir) Plus Ritonavir, d4T, and 3TC (Spring 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Abbott Expands ABT-378/Ritonavir Early-Access Program (February 2000)
In Positive Living, from AIDS Project Los Angeles
ABT-378 "Early Access" Program (December 1999)
In Body Positive, from Body Positive
Treatment News: Expanded Access Program for ABT-378 Under Way (November 1999)
Triangle Pharma Coactinon combo may suppress HIV.
In Positive Living, from AIDS Project Los Angeles
ABT-378 Early Access Program Begins (October 1, 1999)
From AIDS Treatment News
ABT-378: Abbott "Second Generation" Protease Inhibitor (February 21, 1997)
In AIDS Treatment News, from AIDS Treatment News
ABT-378: A New Protease Inhibitor From Abbott (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
More Data on Higher-Dose Lopinavir/Ritonavir (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.